Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Background Agents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the response rate of anti-PD-1/PD-L1 is still unsatisfactory, partly due to immunosuppressive factors such as transforming growth fa...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/12/e005543.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129414434586624 |
|---|---|
| author | Jing Zhang Ming Yi Zhijun Dai Pengfei Zhou Yuze Wu Mengke Niu Shuangli Zhu Yongxiang Yan Kongming Wu |
| author_facet | Jing Zhang Ming Yi Zhijun Dai Pengfei Zhou Yuze Wu Mengke Niu Shuangli Zhu Yongxiang Yan Kongming Wu |
| author_sort | Jing Zhang |
| collection | DOAJ |
| description | Background Agents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the response rate of anti-PD-1/PD-L1 is still unsatisfactory, partly due to immunosuppressive factors such as transforming growth factor-beta (TGF-β). In our previous pilot study, the bispecific antibody targeting TGF-β and murine PD-L1 (termed YM101) showed potent antitumor effect. In this work, we constructed a bispecific antibody targeting TGF-β and human PD-L1 (termed BiTP) and explored the antitumor effect of BiTP in TNBC.Methods BiTP was developed using Check-BODYTM bispecific platform. The binding affinity of BiTP was measured by surface plasmon resonance, ELISA, and flow cytometry. The bioactivity was assessed by Smad and NFAT luciferase reporter assays, immunofluorescence, western blotting, and superantigen stimulation assays. The antitumor activity of BiTP was explored in humanized epithelial-mesenchymal transition-6-hPDL1 and 4T1-hPDL1 murine TNBC models. Immunohistochemical staining, flow cytometry, and bulk RNA-seq were used to investigate the effect of BiTP on immune cell infiltration.Results BiTP exhibited high binding affinity to dual targets. In vitro experiments verified that BiTP effectively counteracted TGF-β-Smad and PD-L1-PD-1-NFAT signaling. In vivo animal experiments demonstrated that BiTP had superior antitumor activity relative to anti-PD-L1 and anti-TGF-β monotherapy. Mechanistically, BiTP decreased collagen deposition, enhanced CD8+ T cell penetration, and increased tumor-infiltrating lymphocytes. This improved tumor microenvironment contributed to the potent antitumor activity of BiTP.Conclusion BiTP retains parent antibodies’ binding affinity and bioactivity, with superior antitumor activity to parent antibodies in TNBC. Our data suggest that BiTP might be a promising agent for TNBC treatment. |
| format | Article |
| id | doaj-art-05f433b81a5d403a8d919af35b46ac9e |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-05f433b81a5d403a8d919af35b46ac9e2025-08-20T02:32:59ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-12-01101210.1136/jitc-2022-005543Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancerJing Zhang0Ming Yi1Zhijun Dai2Pengfei Zhou3Yuze Wu4Mengke Niu5Shuangli Zhu6Yongxiang Yan7Kongming Wu83 School of Public Health, University of New South Wales, Sydney, New South Wales, AustraliaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaWuhan YZY Biopharma Co Ltd, Wuhan, ChinaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaWuhan YZY Biopharma Co Ltd, Wuhan, ChinaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaBackground Agents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the response rate of anti-PD-1/PD-L1 is still unsatisfactory, partly due to immunosuppressive factors such as transforming growth factor-beta (TGF-β). In our previous pilot study, the bispecific antibody targeting TGF-β and murine PD-L1 (termed YM101) showed potent antitumor effect. In this work, we constructed a bispecific antibody targeting TGF-β and human PD-L1 (termed BiTP) and explored the antitumor effect of BiTP in TNBC.Methods BiTP was developed using Check-BODYTM bispecific platform. The binding affinity of BiTP was measured by surface plasmon resonance, ELISA, and flow cytometry. The bioactivity was assessed by Smad and NFAT luciferase reporter assays, immunofluorescence, western blotting, and superantigen stimulation assays. The antitumor activity of BiTP was explored in humanized epithelial-mesenchymal transition-6-hPDL1 and 4T1-hPDL1 murine TNBC models. Immunohistochemical staining, flow cytometry, and bulk RNA-seq were used to investigate the effect of BiTP on immune cell infiltration.Results BiTP exhibited high binding affinity to dual targets. In vitro experiments verified that BiTP effectively counteracted TGF-β-Smad and PD-L1-PD-1-NFAT signaling. In vivo animal experiments demonstrated that BiTP had superior antitumor activity relative to anti-PD-L1 and anti-TGF-β monotherapy. Mechanistically, BiTP decreased collagen deposition, enhanced CD8+ T cell penetration, and increased tumor-infiltrating lymphocytes. This improved tumor microenvironment contributed to the potent antitumor activity of BiTP.Conclusion BiTP retains parent antibodies’ binding affinity and bioactivity, with superior antitumor activity to parent antibodies in TNBC. Our data suggest that BiTP might be a promising agent for TNBC treatment.https://jitc.bmj.com/content/10/12/e005543.full |
| spellingShingle | Jing Zhang Ming Yi Zhijun Dai Pengfei Zhou Yuze Wu Mengke Niu Shuangli Zhu Yongxiang Yan Kongming Wu Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer Journal for ImmunoTherapy of Cancer |
| title | Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer |
| title_full | Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer |
| title_fullStr | Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer |
| title_full_unstemmed | Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer |
| title_short | Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer |
| title_sort | anti tgf β pd l1 bispecific antibody promotes t cell infiltration and exhibits enhanced antitumor activity in triple negative breast cancer |
| url | https://jitc.bmj.com/content/10/12/e005543.full |
| work_keys_str_mv | AT jingzhang antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT mingyi antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT zhijundai antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT pengfeizhou antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT yuzewu antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT mengkeniu antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT shuanglizhu antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT yongxiangyan antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer AT kongmingwu antitgfbpdl1bispecificantibodypromotestcellinfiltrationandexhibitsenhancedantitumoractivityintriplenegativebreastcancer |